Mission Statement, Vision, & Core Values (2026) of Pharmaron Beijing Co., Ltd.

From its founding in 2004 to its current status as a publicly traded leader (ticker 3759.HK), Pharmaron Beijing Co., Ltd. has built an end-to-end CRO platform that merges drug discovery, preclinical and clinical development, and manufacturing for small molecules, biologics and cell & gene therapies-backed by a global team of over 22,000 employees across China, the US and the UK; guided by a mission "to help our partners develop new drugs with the highest level of R&D services and contribute Pharmaron's efforts to human health," and a vision to be "a leading global provider of integrated research, development, and manufacturing solutions," the company invests heavily in innovation and quality systems such as GLP and GMP, while living core values like "Employees Number One" and "Clients Centered" that drive training, diversity, employee welfare, timely and cost-effective partner service, and a collaborative culture that scales its scientific capabilities worldwide.

Pharmaron Beijing Co., Ltd. (3759.HK) - Intro

• Founded: 2004
• Employees: >22,000 (China, US, UK)
• Global footprint: Operations and client partnerships across Asia, North America, and Europe
• Standards: GLP and GMP compliant facilities

• Mission: Deliver high-quality, science-driven R&D and manufacturing solutions that accelerate clients' drug development timelines while maintaining regulatory and ethical excellence.
• Vision: Be the world's most trusted partner for end-to-end drug development and manufacturing across modalities-from discovery to commercial supply.
• Strategic priorities:
  • Expand integrated platform capabilities to support small molecules, biologics, and cell & gene therapies.
  • Invest in advanced analytics, automation, and platform R&D to reduce cycle times and improve predictability.
  • Maintain and expand GLP/GMP-compliant capacity to meet rising global demand.

• Scientific excellence: rigorous, data-driven decision making and continuous technical investment.
• Quality & compliance: adherence to international regulatory standards (GLP, GMP) across all facilities.
• Collaboration: long-term partnerships with biopharma sponsors, unlocking synergistic project design and execution.
• People-first culture: talent development, diversity, inclusion, and employee well-being.
• Innovation: sustained R&D reinvestment to adopt new modalities and technologies.

• Significant R&D investment to enhance platform capabilities and support advanced modalities (cell & gene therapy workflows integrated into preclinical and CMC pipelines).
• Quality systems aligned with GLP and GMP to support regulatory submissions across multiple jurisdictions.
• Continuous improvement programs to optimize timelines, reduce attrition, and improve data integrity for clients.

• Employee base: >22,000 professionals across scientific, technical, regulatory, and manufacturing functions.
• Talent development: internal training, cross-site rotations, and partnerships with academic institutions to build domain expertise.
• Inclusive environment: programs supporting diversity, mental health, and career progression.

Pharmaron Beijing Co., Ltd. (3759.HK) Overview

• Customer-centric R&D services across small molecules, biologics, cell & gene therapy, and advanced analytical platforms.
• Investment-led growth strategy: sustained capital directed toward lab capacity, automation, and technology platforms.
• Global delivery model: integrated service network across China, the U.S., Europe and Asia to support multinational and domestic biopharma clients.

• Scale: expand capacity in biologics, cell & gene and advanced small-molecule chemistry to capture growing outsourcing demand.
• Technology leadership: invest in automation, high-throughput screening, AI/ML for target ID and predictive toxicology.
• Quality & compliance: maintain international regulatory standards (FDA, EMA, NMPA) across facilities to support global filings.
• Sustainability & responsibility: reduce lab energy intensity and enhance biosafety and responsible sourcing across supply chains.

• Scientific excellence - rigorous methods, reproducibility, and continual technical upskilling.
• Client partnership - align KPIs, share risk, and deliver integrated project management focused on timelines and outcomes.
• Innovation - adopt emerging technologies (AI, single-use bioprocessing, continuous manufacturing) to improve speed and cost-efficiency.
• Integrity & compliance - transparent data governance, ethics in research, and adherence to global regulatory expectations.
• Talent development - world-class scientific teams, cross-functional training, and retention through competitive incentives.

• R&D-heavy spending profile: consistent high percentage of revenue reinvested to expand capabilities and services (see R&D spend in table).
• Revenue mix diversification: growing share from biologics and cell & gene services while maintaining strong small-molecule CRO/CMC franchise.
• Global client base expansion: increased revenues from multinational pharmaceutical customers and repeat-business contracting models.

Pharmaron Beijing Co., Ltd. (3759.HK) - Mission Statement

• Integrate research, development, and manufacturing to reduce time-to-market for clients and improve program continuity.
• Deliver high-quality solutions across diverse therapeutic areas, including oncology, CNS, metabolic diseases, and cell & gene therapies.
• Expand global footprint and capabilities to serve multinational pharmaceutical and biotech clients with consistent standards and regulatory readiness.
• Invest in innovative technologies (AI-driven discovery tools, high-throughput platforms, advanced bioprocessing) to increase efficiency and scientific output.

• Provide integrated, scientifically rigorous support across discovery, preclinical, clinical development, and commercial manufacturing to accelerate clients' drug development programs.
• Ensure regulatory-compliant, scalable manufacturing for both small molecules and biologics while maintaining cost-efficiency.
• Act as a trusted partner for biotech and pharma customers by aligning service delivery with client goals and timelines.

• Scientific Excellence - rigorous methodology, continuous capability upgrades, and measurable performance benchmarks.
• Quality & Compliance - adherence to global regulatory standards (ICH, GMP, GLP) across all sites and services.
• Client-Centricity - tailored project governance, transparent milestones, and outcome-oriented partnerships.
• Innovation - adoption of digital tools, automation, and novel platform technologies to improve speed and predictability.
• Collaboration & Integrity - cross-functional teamwork, ethical conduct, and long-term relationship building.

• Global expansion: strengthening presence in North America and Europe to complement Asian operations and serve multinational programs end-to-end.
• Service breadth: expanding biologics and cell/gene therapy capabilities to capture higher value segments of the market.
• Operational metrics: targeting continued mid-teens percentage revenue growth through service mix improvements and cross-selling integrated solutions.

Pharmaron Beijing Co., Ltd. (3759.HK) - Vision Statement

• Employees Number One - Prioritizing talent development, wellbeing, and empowerment to sustain innovation and quality.
• Clients Centered - Delivering timely, cost‑effective, sustainable solutions that enable partners' success from discovery through commercialization.

• Training & development: Companywide average of 40+ formal training hours per employee per year (technical, regulatory, managerial).
• Career growth: Internal promotion rate of ~18% annually (across technical and management tracks).
• Work-life balance: Flexible scheduling and remote/hybrid policies implemented across corporate functions; paid leave and wellness programs offered globally.
• Benefits package: Comprehensive coverage designed to attract and retain global talent, including medical, dental, and vision plans; retirement savings plans with employer match for eligible jurisdictions.

• Service quality: Client satisfaction scores above industry benchmarks (net promoter and satisfaction indices maintained via continuous feedback loops).
• Speed & cost efficiency: Optimized CRO/Tox and chemistry workflows that reduce typical discovery timelines by up to 20% for select programs.
• Sustainability: Investment in greener lab practices and supply chain improvements to lower environmental footprint while maintaining service consistency.

• Employee investment directly supports client outcomes: better-trained scientists and technicians increase delivery speed and quality, strengthening client retention and new business wins.
• Clients‑centered processes are reinforced by measurable KPIs (turnaround times, cost per assay, defect rates) that feed continuous improvement cycles.
• Benefits and inclusion initiatives reduce turnover and foster cross‑functional collaboration across global sites, underpinning sustainable revenue growth and margin stability.